The identification of genes linked to patient outcomes and immune components in the tumor microenvironment further underscores the notion that KRAS signaling does not operate in isolation but rather interconnects with immunological mediators, including macrophage-dependent processes (28). This evidence concerns the gene KRAS and neoplasm.